Abeona Net Receivables from 2010 to 2024

ABEO Stock  USD 6.03  0.09  1.52%   
Abeona Therapeutics Net Receivables yearly trend continues to be very stable with very little volatility. Net Receivables is likely to grow to about 2.6 M this year. During the period from 2010 to 2024, Abeona Therapeutics Net Receivables quarterly data regression pattern had sample variance of 1.1 T and median of  115,000. View All Fundamentals
 
Net Receivables  
First Reported
1997-09-30
Previous Quarter
1.6 M
Current Value
1.6 M
Quarterly Volatility
1.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Abeona Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abeona Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 397.1 K or Selling General Administrative of 18.1 M, as well as many indicators such as Price To Sales Ratio of 29.07, Dividend Yield of 1.6 K or PTB Ratio of 7.59. Abeona financial statements analysis is a perfect complement when working with Abeona Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Abeona Therapeutics Correlation against competitors.
To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.

Latest Abeona Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Abeona Therapeutics over the last few years. It is Abeona Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abeona Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Abeona Net Receivables Regression Statistics

Arithmetic Mean663,680
Geometric Mean0.00
Coefficient Of Variation160.37
Mean Deviation826,064
Median115,000
Standard Deviation1,064,321
Sample Variance1.1T
Range3M
R-Value0.58
Mean Square Error815.7B
R-Squared0.33
Significance0.02
Slope136,998
Total Sum of Squares15.9T

Abeona Net Receivables History

20242.6 M
20232.4 M
2022188 K
2021M
2019null
201881 K
2017107 K

About Abeona Therapeutics Financial Statements

Abeona Therapeutics investors utilize fundamental indicators, such as Net Receivables, to predict how Abeona Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables2.4 M2.6 M

Pair Trading with Abeona Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Abeona Stock

  0.89OPT OptheaPairCorr

Moving against Abeona Stock

  0.78FDMT 4D Molecular TherapeuticsPairCorr
  0.67INKT Mink TherapeuticsPairCorr
  0.66RGNX RegenxbioPairCorr
  0.52NKTX Nkarta IncPairCorr
  0.42MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock:
Check out the analysis of Abeona Therapeutics Correlation against competitors.
To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.38)
Return On Equity
(1.27)
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.